BlossomHill Therapeutics (NASDAQ:BLSM) Stock Price Up 5.8% - What's Next?

Key Points

• BlossomHill Therapeutics shares rose 5.8% to $23.46 in mid-day trading, though volume was 82% below the average session volume.
• Analyst sentiment remains favorable, with five Buy ratings and one Hold rating producing a “Moderate Buy” consensus and an average price target of $32.20.
• Insiders made significant purchases, acquiring 1,573,900 shares worth approximately $25.2 million during the last quarter, including two directors’ combined $15 million purchases on August 10.

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM - Get Free Report)'s share price traded up 5.8% on Wednesday . The company traded as high as $23.60 and last traded at $23.46. 35,999 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 197,364 shares. The stock had previously closed at $22.17.

Analyst Ratings Changes

Several research firms have recently commented on BLSM. Zacks Research raised shares of BlossomHill Therapeutics to a "hold" rating in a research report on Wednesday, September 2nd. Wall Street Zen upgraded BlossomHill Therapeutics to a "hold" rating in a research note on Saturday, August 15th. HC Wainwright initiated coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set a "buy" rating and a $35.00 price objective for the company. Lifesci Capital started coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an "outperform" rating and a $32.00 price objective for the company. Finally, JPMorgan Chase & Co. started coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an "overweight" rating and a $28.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $32.20.

BlossomHill Therapeutics Stock Performance

Insider Buying and Selling

In other BlossomHill Therapeutics news, Director Carl Gordon purchased 625,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the director owned 2,714,279 shares of the company's stock, valued at $43,428,464. The trade was a 29.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bihua Chen purchased 312,500 shares of the company's stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the acquisition, the director directly owned 3,614,034 shares of the company's stock, valued at $57,824,544. This trade represents a 9.47% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 1,573,900 shares of company stock valued at $25,181,900 over the last quarter.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.